Skip to Main Content

Paper Details

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Lancet Oncology, The
151
2018
Patients, acute lung injury, acute respiratory distress syndrome, anaemia, bortezomib, cardiac failure, carfilzomib, congestive heart, dexamethasone, ixazomib, multiple myeloma, patients, plasma cell myeloma, pneumonia, relapsed and refractory, sepsis, thrombocytopenia, tumour lysis syndrome

Datasets

Release 1.2